Published in Proc Natl Acad Sci U S A on December 05, 2008
Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol (2009) 3.31
Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol (2013) 1.90
The crystal structures of substrate and nucleotide complexes of Enterococcus faecium aminoglycoside-2''-phosphotransferase-IIa [APH(2'')-IIa] provide insights into substrate selectivity in the APH(2'') subfamily. J Bacteriol (2009) 1.27
Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res (2009) 1.14
Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol (2013) 1.10
Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells. Proc Natl Acad Sci U S A (2010) 1.10
Structure of the activating IL-1 receptor signaling complex. Nat Struct Mol Biol (2012) 1.06
Structure of the bifunctional isocitrate dehydrogenase kinase/phosphatase. Nature (2010) 1.00
Grb2, a double-edged sword of receptor tyrosine kinase signaling. Sci Signal (2012) 0.96
Cracking the molecular origin of intrinsic tyrosine kinase activity through analysis of pathogenic gain-of-function mutations. Cell Rep (2013) 0.93
The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia (2013) 0.90
The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition. Structure (2012) 0.85
Structural mimicry of a-loop tyrosine phosphorylation by a pathogenic FGF receptor 3 mutation. Structure (2013) 0.84
Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans. Mol Cell (2014) 0.83
Plasticity in interactions of fibroblast growth factor 1 (FGF1) N terminus with FGF receptors underlies promiscuity of FGF1. J Biol Chem (2011) 0.83
Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy. ACS Chem Biol (2015) 0.81
Structural and mechanistic insights into the bifunctional enzyme isocitrate dehydrogenase kinase/phosphatase AceK. Philos Trans R Soc Lond B Biol Sci (2012) 0.81
The structural biology of the FGF19 subfamily. Adv Exp Med Biol (2012) 0.81
Coarse-grained molecular simulation of epidermal growth factor receptor protein tyrosine kinase multi-site self-phosphorylation. PLoS Comput Biol (2014) 0.80
Regulatory interactions between a bacterial tyrosine kinase and its cognate phosphatase. J Biol Chem (2013) 0.80
Structure of Full-Length Human PDGFRβ Bound to Its Activating Ligand PDGF-B as Determined by Negative-Stain Electron Microscopy. J Mol Biol (2015) 0.79
Two FGF Receptor Kinase Molecules Act in Concert to Recruit and Transphosphorylate Phospholipase Cγ. Mol Cell (2015) 0.77
Coupling of transmembrane helix orientation to membrane release of the juxtamembrane region in FGFR3. Biochemistry (2014) 0.77
Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinases. Sci Signal (2015) 0.77
Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases. Elife (2017) 0.75
Effects of FGFR2 kinase activation loop dynamics on catalytic activity. PLoS Comput Biol (2017) 0.75
An electrostatic selection mechanism controls sequential kinase signaling downstream of the T cell receptor. Elife (2016) 0.75
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A (1991) 119.63
Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem (1996) 45.70
Cell signaling by receptor tyrosine kinases. Cell (2000) 18.16
Signaling--2000 and beyond. Cell (2000) 11.78
Shape complementarity at protein/protein interfaces. J Mol Biol (1993) 10.40
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell (2006) 10.28
Theory for the folding and stability of globular proteins. Biochemistry (1985) 5.92
Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell (2004) 5.02
Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J (1997) 4.59
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem (2004) 3.79
Structural basis for the autoinhibition of focal adhesion kinase. Cell (2007) 3.18
Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis. Nature (1992) 3.13
Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell (1996) 2.75
A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell (2007) 2.70
Structural basis for the inhibition of tyrosine kinase activity of ZAP-70. Cell (2007) 2.68
Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol (2001) 2.45
Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol Cell (2006) 2.21
Characterization of pp60c-src tyrosine kinase activities using a continuous assay: autoactivation of the enzyme is an intermolecular autophosphorylation process. Biochemistry (1995) 2.13
Structure of a c-kit product complex reveals the basis for kinase transactivation. J Biol Chem (2003) 1.95
Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem (2006) 1.72
Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. Mol Cell Endocrinol (2006) 1.62
Protein-protein interactions in the allosteric regulation of protein kinases. Curr Opin Struct Biol (2006) 1.49
Receptor signaling: when dimerization is not enough. Curr Biol (1999) 1.42
Mechanistic diversity of cytokine receptor signaling across cell membranes. Sci STKE (2004) 1.42
Structure of the Tie2 RTK domain: self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail. Structure (2000) 1.32
Kallmann syndrome: 14 novel mutations in KAL1 and FGFR1 (KAL2). Hum Mutat (2005) 1.23
Paediatric phenotype of Kallmann syndrome due to mutations of fibroblast growth factor receptor 1 (FGFR1). Mol Cell Endocrinol (2006) 1.15
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc Natl Acad Sci U S A (2003) 1.15
Autoinhibitory mechanisms in receptor tyrosine kinases. Front Biosci (2002) 1.01
The structure, organization, activation and plasticity of the erythropoietin receptor. Curr Opin Struct Biol (1999) 0.99
The minimum information about a proteomics experiment (MIAPE). Nat Biotechnol (2007) 10.24
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab (2007) 9.62
The genome of the choanoflagellate Monosiga brevicollis and the origin of metazoans. Nature (2008) 6.69
The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 6.23
Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem (2006) 5.78
The parathyroid is a target organ for FGF23 in rats. J Clin Invest (2007) 4.47
Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem (2007) 4.42
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res (2002) 4.19
BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A (2007) 4.00
FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A (2009) 3.99
Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol (2007) 3.73
The CD26-related dipeptidyl aminopeptidase-like protein DPPX is a critical component of neuronal A-type K+ channels. Neuron (2003) 3.50
Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. Genes Dev (2010) 3.49
The matrix peptide exporter HAF-1 signals a mitochondrial UPR by activating the transcription factor ZC376.7 in C. elegans. Mol Cell (2010) 3.26
Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest (2007) 3.20
Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res (2010) 3.08
Impaired FGF signaling contributes to cleft lip and palate. Proc Natl Acad Sci U S A (2007) 2.94
A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest (2007) 2.79
Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab (2008) 2.76
A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell (2007) 2.70
Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest (2008) 2.69
Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol (2010) 2.67
Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med (2007) 2.54
Oxidative protein folding by an endoplasmic reticulum-localized peroxiredoxin. Mol Cell (2010) 2.51
Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology (2005) 2.46
The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. Proc Natl Acad Sci U S A (2012) 2.45
Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance. Mol Cell Proteomics (2009) 2.39
Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc Natl Acad Sci U S A (2012) 2.38
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res (2005) 2.27
Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A (2009) 2.23
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol (2011) 2.20
Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. Proc Natl Acad Sci U S A (2010) 2.10
Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev (2005) 2.10
Performance metrics for liquid chromatography-tandem mass spectrometry systems in proteomics analyses. Mol Cell Proteomics (2009) 2.09
The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. J Biol Chem (2009) 2.06
Identification and verification of novel rodent postsynaptic density proteins. Mol Cell Proteomics (2004) 2.03
In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis. FASEB J (2008) 2.03
The protist, Monosiga brevicollis, has a tyrosine kinase signaling network more elaborate and diverse than found in any known metazoan. Proc Natl Acad Sci U S A (2008) 2.00
Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol (2007) 1.96
Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet (2004) 1.92
Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum. J Clin Endocrinol Metab (2008) 1.92
Guidelines for reporting the use of mass spectrometry in proteomics. Nat Biotechnol (2008) 1.90
Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol (2013) 1.90
Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res (2008) 1.87
Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci U S A (2006) 1.87
Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J Biol Chem (2003) 1.86
ABRF-PRG03: phosphorylation site determination. J Biomol Tech (2003) 1.83
Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene (2004) 1.83
FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol (2009) 1.70
Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci U S A (2004) 1.70
Canonical and alternate functions of the microRNA biogenesis machinery. Genes Dev (2010) 1.67
Structural and biochemical characterization of the KRLB region in insulin receptor substrate-2. Nat Struct Mol Biol (2008) 1.67
Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Hum Mol Genet (2003) 1.66
Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Proc Natl Acad Sci U S A (2003) 1.62
Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. Mol Cell Endocrinol (2006) 1.62
Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab (2007) 1.56
Crystal structure of a fibroblast growth factor homologous factor (FHF) defines a conserved surface on FHFs for binding and modulation of voltage-gated sodium channels. J Biol Chem (2009) 1.56
GNRH1 mutations in patients with idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci U S A (2009) 1.55
Proteasomal adaptation to environmental stress links resistance to proteotoxicity with longevity in Caenorhabditis elegans. Proc Natl Acad Sci U S A (2008) 1.54
FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis. J Cell Biol (2008) 1.53
Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med (2011) 1.51
Proteomic analysis of exfoliation deposits. Invest Ophthalmol Vis Sci (2007) 1.47
Stable isotopic labeling by amino acids in cultured primary neurons: application to brain-derived neurotrophic factor-dependent phosphotyrosine-associated signaling. Mol Cell Proteomics (2008) 1.46
FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One (2012) 1.45
Managing delayed or altered puberty in boys. BMJ (2012) 1.43